Research Article
ITIH4: A New Potential Biomarker of “Toxin Syndrome” in Coronary Heart Disease Patient Identified with Proteomic Method
Table 1
Baseline information of two groups in RCT.
| | Groups | Group A | Group B |
| | Age | | | | Minimum value (years) | 48 | 42 | | Maximum value (years) | 74 | 75 | | Mean value (years) | 61.94 ± 8.41 | 61.24 ± 9.86 | | Sex | | | | Male (proportion) | 22 (71%) | 25 (86.2%) | | Female (proportion) | 9 (29%) | 5 (13.8%) | | Angina score | 14.42 ± 4.86 | 14.89 ± 4.63 | | Primary symptom score of TCM | 17.97 ± 6.74 | 18.94 ± 5.64 | | BSS score | 10.89 ± 4.62 | 10.59 ± 3.38 | | Past history | | | | Hypertension () | 18 | 16 | | Diabetes () | 7 | 9 | | Dislipidemia () | 11 | 12 | | Stroke () | 2 | 4 | | Peripheral vascular atherosclerosis () | 5 | 3 | | Old myocardial infarction () | 4 | 1 | | Western medicine | | | | Aspirin () | 31 | 30 | | Clopidogrel hydrogen sulfate () | 31 | 30 | | Nitrates () | 21 | 16 | | β-blocker () | 28 | 30 | | ACEI/ARB () | 19 | 17 | | CCB () | 3 | 9 | | Low molecular weight heparin () | 16 | 19 | | Statins () | 30 | 29 | | UA risk stratification | | | | Low risk () | 0 | 0 | | Mediate risk () | 26 | 24 | | High risk () | 5 | 6 | | Number of stenosed coronary vessel | | | | 1 vessel () | 8 | 12 | | 2 vessels () | 12 | 7 | | 3 vessels () | 11 | 11 | | Lesions nature | | | | De novo () | 28 | 26 | | Restenosis () | 3 | 4 | | Stent type | | | | Sirolimus-eluting stent () | 21 | 21 | | paclitaxel-eluting stent () | 8 | 6 | | Mixed drug-eluting stents () | 2 | 3 | | Total length of stents | 22.94 ± 7.23 | 21.67 ± 9.69 |
|
|
Note: group A patients have taken the Xiongshao capsule; group B patients have taken the Xiongshao capsule and Huanglian capsule.
|
